BACKGROUND: The effect of @entity10211 on muscle is considered to be uncommon and benign. We analyzed the files of all our @entity1 given @entity10211 over a 5-year period and determined the incidence and gravity of its effect on muscles. MATERIALS AND METHODS: Sixty treatments with @entity10211 were studied. @entity925 and elevated @entity9153 observed at the pretherapeutic consultation and each month or 2 months thereafter were recorded. RESULTS: Muscle symptoms were noted in 60 p. 100 of the cases: @entity925 in 51 p. 100 and elevated @entity9153 in 41 p. 100. In this group, male sex (H/F = 2.6) and sports activities (70 p. 100) were found more often. In 5 @entity1 , @entity9153 level was 5 times the normal, defining @entity5925 . One @entity1 interrupted treatment because of persistently high @entity9153 levels. DISCUSSION: @entity925 and elevated @entity9153 signal skeletal muscle involvement. These signs were more frequent in our series than in reports in the literature, probably because we systematically looked for them. Besides use of @entity10211 , one case of @entity1800 and sports activities, no other explanatory cause could be found. @entity10211 could have a potentializing effect on other myotoxicity inducers (drugs, @entity221 ...). The benign nature of the muscle effect appears to be validated although there were some @entity1 who had persistent and/or severe signs.

[Muscular damage during XXXX treatment].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity9153 :: ('5286', 'Gene') :: ['CPK'] @entity5925 :: ('MESH:D012206', 'Disease') :: ['rhabdomyolysis'] @entity10211 :: ('MESH:D015474', 'Chemical') :: ['isotretinoin', 'Isotretinoin'] @entity1800 :: ('MESH:D014777', 'Disease') :: ['viral infection'] @entity925 :: ('MESH:D063806', 'Disease') :: ['Myalgia', 'myalgia'] @entity221 :: ('MESH:D005334', 'Disease') :: ['infection, fever, muscular exertion']
@entity10211 :: (MESH:D015474,Chemical) :: ['isotretinoin']
